Highest vs lowest quartile of serum phosphorus is independently associated with a nearly 3-fold increased risk of diabetic nephropathy progression.
Among US dialysis patients, cardiovascular event rates are highest in those with diabetic nephropathy and lowest among those with IgA nephropathy.
A clinical trial assessing canagliflozin (Invokana; Janssen) as an addition to standard-of-care in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) has been stopped early after meeting its pre-specified efficacy criteria.
In the AWARD-7 trial, patients who received Trulicity 0.75mg or 1.5mg in combination with mealtime insulin lispro achieved similar glycemic control with weight loss vs patients who received traditional basal-bolus insulin.
Dulaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist.
Patients with higher levels of serum fibrinogen have higher rates of progression.
Much steeper decline in adjusted mean eGFR for those with diagnosed diabetes versus those without.
New study shows metformin is not associated with an increased risk of acidosis in patients with type 2 diabetes and an eGFR of 30 to 60 mL/min/1.73 m2.
Women who had gestational diabetes more likely to show increased eGFR levels many years postpartum
Genome-wide association study identified novel signal near GABRR1, which was not seen in Asians.
Relative risk of end-stage renal disease was 0.13 in those diagnosed in 1995-2011 versus 1965-1979.
Nearly 86% of diabetic nephropathy patients from an Egyptian outpatient center had elevated iPTH levels.
2000 to 2014 saw decrease in incidence of ESRD with diabetes listed as the primary cause.
Proteinuria and renin-angiotensin-aldosterone system inhibitors are independently associated with a significant 6-fold increased odds for anemia in patients with diabetic nephropathy.
End-stage renal disease developed in similar proportions of diabetics regardless of whether they had intensive or standard glycemic control.
Biomarkers apoA4, CD5L, C1QB, and IBP3 may improve the prediction of rapid decline in renal function independently of recognized clinical risk factors in T2DM.
Liraglutide-treated patients were 22% less likely than placebo recipients to experience a composite outcome of renal events.
Almost 40% of pre-dialysis patients with stage 4-5 CKD patients and type 2 diabetes had lab results suggesting low turnover bone disease.
There was a significant association for Trp with the event of rapid decline in eGFR.
Higher levels of sRAGE were significantly associated with incidence of DN after adjustment for duration of diabetes.
Of the children who developed acute kidney injury, 34.9% had stage 1, 45.3% had stage 2, and 19.8% had stage 3.
DPP-4 inhibitors use was used in 54% of treatment visits by the last quarter of 2014; ACEIs and ARBs were prescribed in the majority of treatment visits with peaks above 90%.
Valsartan reduced the incidence of microalbuminuria in IGT without increasing the incidence of hyperkalemia or renal dysfunction compared with placebo.
Poor glycemic control linked to increased prevalence and severity of periodontitis.
Use of the glucagon-like peptide-1 receptor agonist lowered 24-hour urinary albumin excretion rate by 32% over 12 weeks versus placebo.
Findings in large cohort of patients with diabetes over 4 years of follow-up.
AGEs improve RFL prediction in American-Indians with type 2 diabetes.
No change in overall prevalence from 1988 to 2014; decrease in albuminuria, increase in reduced eGFR.
Incident or worsening nephropathy was observed in 12.7% of patients receiving empagliflozin compared with 18.8% of those receiving placebo.
Length of time spent in remission inversely related to risk of microvascular disease.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)